Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Leukemia Clinical Trial

Official title:

A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00005823
• Other study ID #: CDR0000067831
• Secondary ID: LRF-AML14EU-2001
• Status: Completed
• Phase: Phase 3
• First received: June 2, 2000
• Last updated: December 17, 2013
• Start date: December 1998
• Est. completion date: December 2007

Study information

• Verified date: September 2006
• Source: National Cancer Institute (NCI)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known if stronger doses of chemotherapy given over a longer period of time are as well tolerated or as effective as less intensive chemotherapy.

PURPOSE: This randomized phase III trial is studying intensive regimens of chemotherapy to see how well they work compared to nonintensive regimens of chemotherapy in treating older patients with acute myeloid leukemia or myelodysplastic syndrome.

Description:

OBJECTIVES:

• Compare the response rate, survival, quality of life, and supportive care requirements with intensive versus nonintensive chemotherapy in older patients with acute myeloid leukemia or high risk myelodysplastic syndrome.

• Compare response achievement, response duration, survival, toxicity and supportive care requirements with differing doses of daunorubicin and cytarabine in these patients receiving intensive chemotherapy.

• Determine the efficacy of PSC 833 in enhancing the effects of daunorubicin in these patients receiving intensive chemotherapy.

• Compare relapse rate, deaths in complete remission, disease free survival, and survival with short versus long intensive chemotherapy in these patients.

• Compare response achievement, response duration, survival, toxicity, quality of life, and resource use with hydroxyurea versus cytarabine in these patients receiving low dose chemotherapy.

• Determine response achievement, response duration, survival, toxicity, quality of life, and supportive care requirements with the addition of tretinoin to the nonintensive chemotherapy in these patients.

• Assess the correlation between P-gp and BCL-2 in family members and treatment outcomes and other prognostic factors in these patients with these treatment regimens.

OUTLINE: This is a randomized, multicenter study. Patients are randomized or electively assigned to either intensive or nonintensive chemotherapy*.

Intensive chemotherapy

• Induction therapy: Patients are randomized to 1 of 6 treatment arms. Patients receive 2 courses of chemotherapy comprising 1 of 2 daunorubicin doses, 1 of 2 cytarabine doses, thioguanine, and with or without PSC 833.

Patients receive daunorubicin IV once daily on days 1-3 with cytarabine IV twice daily and oral thioguanine once daily on days 1-10 during course 1. Treatment repeats in approximately 31 days as in course 1 except cytarabine and thioguanine are given only on days 1-8.

• Arm I: Patients receive higher dose of daunorubicin, lower dose of cytarabine, and thioguanine.

• Arm II: Patients receive higher dose of daunorubicin, higher dose of cytarabine, and thioguanine.

• Arm III: Patients receive lower dose of daunorubicin, lower dose of cytarabine, and thioguanine.

• Arm IV: Patients receive lower dose of daunorubicin, higher dose of cytarabine, and thioguanine.

• Arm V: Patients receive treatment as in arm III in combination with continuous infusion of PSC 833 beginning day 1.

• Arm VI: Patients receive treatment as in arm IV in combination with continuous infusion of PSC 833 beginning on day 1.

Patients with refractory disease after the first course of induction chemotherapy may continue with the intensive protocol arm or enter the nonintensive arm*. Patients who do not achieve complete remission after completion of induction chemotherapy are removed from study. Patients in complete remission after induction therapy receive consolidation therapy.

• Consolidation therapy: Patients in complete remission after induction are randomized to either short or long consolidation.

• Short consolidation: Patients receive mitoxantrone IV on days 1-3 and cytarabine IV over 2 hours twice daily on days 1-3.

• Long consolidation: Patients complete short consolidation and then receive idarubicin IV over 5 minutes once daily on days 1 and 3, cytarabine IV over 2 hours twice daily and etoposide IV over 1 hour once daily on days 1-3.

Non-intensive chemotherapy*

• Patients are randomized to 1 of 4 treatment arms.

• Arm I: Patients receive oral hydroxyurea as necessary to control WBC count until treatment failure.

• Arm II: Patients receive hydroxyurea as in arm I and oral tretinoin daily for up to 16 weeks.

• Arm III: Patients receive low dose cytarabine subcutaneously twice daily on days 1-10 every 28 days for a minimum of 4 courses.

• Arm IV: Patients receive cytarabine as in arm III plus oral tretinoin daily for up to 16 weeks.

NOTE: *Patients with liver function test > 2 times upper limit of normal are not eligible for nonintensive randomization

Quality of life is assessed at study entry, and then at 1, 3, and 6 months.

Patients are followed at one year.

PROJECTED ACCRUAL: Approximately 2,000 patients (1,200 to intensive arm and 800 to nonintensive arm) will be accrued for this study over 5 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2000
• Est. completion date: December 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 60 Years and older

Eligibility

DISEASE CHARACTERISTICS:

• Acute myeloid leukemia (de novo or secondary) OR

• Myelodysplastic syndrome

• More than 10% myeloblasts in the bone marrow

• Refractory anemia with excess blasts

• Refractory anemia with excess blasts in transformation

• Chronic myelomonocytic leukemia

• No acute promyelocytic leukemia (FAB type M3)

• No blastic phase chronic myeloid leukemia

PATIENT CHARACTERISTICS:

Age:

• 60 and over (younger patients allowed if intensive chemotherapy not indicated)

Performance status:

• Not specified

Life expectancy:

• Not specified

Hematopoietic:

• Not specified

Hepatic:

• No liver function test = 2 times normal (for non-intensive therapy arm)

Renal:

• Not specified

Cardiovascular:

• No myocardial infarction within past 6 months in patients receiving daunorubicin or PSC 833

Other:

• No other concurrent active malignancy

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• Not specified

Chemotherapy:

• No prior cytotoxic chemotherapy for leukemia

Endocrine therapy:

• Not specified

Radiotherapy:

• Not specified

Surgery:

• Not specified

Study Design

Allocation: Randomized, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute
• Myelodysplastic Syndromes
• Myelodysplastic-Myeloproliferative Diseases
• Myelodysplastic/Myeloproliferative Neoplasms
• Myeloproliferative Disorders
• Preleukemia
• Syndrome

Intervention

Drug:
• cytarabine

• daunorubicin hydrochloride

• etoposide

• hydroxyurea

• idarubicin

• mitoxantrone hydrochloride

• thioguanine

• tretinoin

• valspodar

Locations

Country	Name	City	State
United Kingdom	Queen Elizabeth Hospital at University of Birmingham	Birmingham	England
United Kingdom	University Hospital of Wales	Cardiff	Wales
United Kingdom	University College Hospital	London	England

Sponsors (1)

Lead Sponsor	Collaborator
Leukemia Research Fund

Country where clinical trial is conducted

United Kingdom, 

References & Publications (7)

Burnett AK, Milligan D, Goldstone A, Prentice A, McMullin MF, Dennis M, Sellwood E, Pallis M, Russell N, Hills RK, Wheatley K; United Kingdom National Cancer Research Institute Haematological Oncology Study Group. The impact of dose escalation and resista — View Citation

Burnett AK, Milligan D, Hills RK, et al.: Does all-transretinoic acid (ATRA) have a role in non-APL acute myeloid leukaemia? Results from 1666 patients in three MRC trials. [Abstract] Blood 104 (11): A-1794, 2004.

Burnett AK, Milligan D, Prentice AG, et al.: Low dose Ara-C versus hydroxyurea with or without retinoid in older patients not considered fit for intensive chemotherapy: the UK NCRI AML14 trial. [Abstract] Blood 104 (11): A-872, 2004.

Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, Wheatley K. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients — View Citation

Burnett AK, Milligan DW, Prentice AG, et al.: Modification or dose or treatment duration has no impact on outcome of AML in older patients: preliminary results of the UK NCRI AML14 trial. [Abstract] Blood 106 (11): A-543, 2005.

Pallis M, Truran L, Grundy M, et al.: P-Glycoprotein overexpresion and internal tandem duplications of FLT3 are characteristic of discrete populations of elderly AML patients. [Abstract] Blood 104 (11): A-196, 2004.

Seedhouse CH, Grundy M, White P, Li Y, Fisher J, Yakunina D, Moorman AV, Hoy T, Russell N, Burnett A, Pallis M; National Cancer Research Network. Sequential influences of leukemia-specific and genetic factors on p-glycoprotein expression in blasts from 817 patients entered into the National Cancer Research Network acute myeloid leukemia 14 and 15 trials. Clin Cancer Res. 2007 Dec 1;13(23):7059-66. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Survival			No
Primary	Response achievement			No
Primary	Response duration			No
Secondary	Toxicity by WHO Toxicity Grading after each treatment course			Yes
Secondary	Quality of life EORTC QLQ-C30 at 3 days, 1 month, 3 months, and 6 months from study entry			No
Secondary	Resource use (use of blood products, antibiotics and days in hospital) after each treatment course			No